Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
Int J Gynecol Cancer. 2009 Dec;19(9):1521-3. doi: 10.1111/IGC.0b013e3181a83fbf.
Recent studies have indicated that the risk associated with tamoxifen may be substantially higher for uterine malignant mixed müllerian tumors and uterine sarcomas.
We present 2 cases of ovarian carcinosarcomas in patients with a personal history of breast carcinoma who were treated for a prolonged period with tamoxifen.
To our knowledge, these 2 cases are the first to describe the possible association between ovarian carcinosarcomas and previous personal and familial history of breast carcinoma and\or prolonged use of tamoxifen. These cases may suggest that like in the uterus, tamoxifen has a possible delayed effect, which might be responsible for the formation of aggressive tumors of unclear pathogenesis in the ovaries.
最近的研究表明,他莫昔芬与子宫恶性混合米勒管肿瘤和子宫肉瘤相关的风险可能显著增加。
我们报告了 2 例卵巢癌肉瘤病例,这些患者均有乳腺癌个人病史,并长期接受他莫昔芬治疗。
据我们所知,这 2 例病例首次描述了卵巢癌肉瘤与乳腺癌个人和家族病史以及/或长期使用他莫昔芬之间可能存在的关联。这些病例可能表明,与子宫一样,他莫昔芬可能具有延迟作用,这可能导致卵巢中形成发病机制不明的侵袭性肿瘤。